newsfilter
← Latest News
GlobeNewswire·

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

Updated safety data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose (RP2D)Improved efficacy with one partial response (PR) improving to a complete response (CR), two additional patients with